109 related articles for article (PubMed ID: 31119682)
1. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer.
Usiskin I; Li F; Irwin ML; Cartmel B; Sanft T
Breast Cancer; 2019 Nov; 26(6):719-728. PubMed ID: 31119682
[TBL] [Abstract][Full Text] [Related]
2. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
3. Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
Usiskin I; Li F; Irwin ML; Cartmel B; Sanft T
Breast Cancer Res Treat; 2021 Feb; 186(1):191-197. PubMed ID: 33125620
[TBL] [Abstract][Full Text] [Related]
4. Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients.
Elsamany S; Alzahrani A; Abozeed WN; Rasmy A; Farooq MU; Elbiomy MA; Rawah E; Alsaleh K; Abdel-Aziz NM
Breast; 2015 Oct; 24(5):576-81. PubMed ID: 26071795
[TBL] [Abstract][Full Text] [Related]
5. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
Lin D; Sturgeon KM; Muscat JE; Zhou S; Hobkirk AL; O'Brien KM; Sandler DP; Thompson CL
Breast Cancer; 2024 May; 31(3):519-528. PubMed ID: 38564089
[TBL] [Abstract][Full Text] [Related]
6. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
[TBL] [Abstract][Full Text] [Related]
7. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L; Greenup R; Niemierko A; Schapira L; Haddad S; Jimenez R; Coopey S; Taghian A; Hughes KS; Isakoff SJ; Ellisen LW; Smith BL; Specht M; Moy B; Bardia A
J Natl Compr Canc Netw; 2017 Oct; 15(10):1216-1223. PubMed ID: 28982747
[No Abstract] [Full Text] [Related]
8. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
9. BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.
Erbes T; Stickeler E; Rücker G; Buroh S; Asberger J; Dany N; Thornton S; Iborra S; Hirschfeld M; Gitsch G; Mayer S
Clin Breast Cancer; 2016 Aug; 16(4):e119-32. PubMed ID: 27067040
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
11. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
12. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
13. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Beresford MJ; Burcombe R; Ah-See ML; Stott D; Makris A
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):453-8. PubMed ID: 16909968
[TBL] [Abstract][Full Text] [Related]
15. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
LeVasseur N; Sun J; Gondara L; Diocee R; Speers C; Lohrisch C; Chia S
J Cancer Res Clin Oncol; 2020 Feb; 146(2):529-536. PubMed ID: 31741041
[TBL] [Abstract][Full Text] [Related]
16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
17. Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
Baker JL; Di Meglio A; Gbenou AS; El Mouhebb M; Iyengar NM; Michiels S; Cottu P; Lerebours F; Coutant C; Lesur A; Tredan O; Vanlemmens L; Jouannaud C; Hrab I; Everhard S; Martin AL; Arveux P; Fabrice A; Vaz-Luis I; Jones LW
Br J Cancer; 2022 Sep; 127(5):886-891. PubMed ID: 35715631
[TBL] [Abstract][Full Text] [Related]
18. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Warner ET; Ballman KV; Strand C; Boughey JC; Buzdar AU; Carey LA; Sikov WM; Partridge AH
Breast Cancer Res Treat; 2016 Aug; 159(1):109-18. PubMed ID: 27449492
[TBL] [Abstract][Full Text] [Related]
19. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.
Hyun SH; Ahn HK; Park YH; Im YH; Kil WH; Lee JE; Nam SJ; Cho EY; Choi JY
Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075
[TBL] [Abstract][Full Text] [Related]
20. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Litton JK; Gonzalez-Angulo AM; Warneke CL; Buzdar AU; Kau SW; Bondy M; Mahabir S; Hortobagyi GN; Brewster AM
J Clin Oncol; 2008 Sep; 26(25):4072-7. PubMed ID: 18757321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
